Menlo Park, California, United States
Head of Life Sciences and Managing Partner at Abingworth, a leading life science investment firm with offices in London, Menlo Park CA, and Boston. We focus on therapeutic investment opportunities, from preclinical to commercial. We are investing out of our 14th venture fund, Abingworth Bioventures 9. I am based in the California but work on global sourcing and execution of deals.
Abingworth invests in private and public life sciences companies. We are currently investing ~$1.5b in funds.
Iambic Therapeutics combines physics and AI to create a differentiated drug discovery platform to quickly and efficiently create potentially best-in-class molecules.
Orbus is a phase 3 oncology company. Eflornithine is a novel cytostatic agent that inhibits tumor growth by preventing cell division and proliferation which Orbus Therapeutics is developing for the treatment of patients with anaplastic astrocytoma (AA), or Grade 3 glioma, a rare and deadly form of brain cancer. Eflornithine irreversibly blocks ornithine decarboxylase (ODC), a key enzyme associated with various types of cancer.
SFJ Pharmaceuticals® is a global specialty pharmaceutical company with an innovative pharmaceutical co-development model that provides an advantageous alternative to traditional pharma partnerships. SFJ Pharmaceuticals®’s unique partnering approach provides experienced clinical and medical professionals, clinical development resources and operational oversight and execution to accelerate late-phase drug development candidates across multiple indications and therapeutic areas. The result is pipeline acceleration for our partners.